Responses to parliamentary questions
Question from Deputy Ken O'Flynn - PQ 15814-26
Deputy O'Flynn asked about the pharmacoeconomic evaluations of tirzepatide and semaglutide. Read the HSE response.
Published: February 2026
Updated: March 2026
Documents
Question from Deputy Ken O'Flynn - PQ 15814-26
PDF, 620KB, 2 pages
Summary
To ask the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes.
This is a beta version - your feedback will help us to improve it